Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual doppelgänger may help pick right patients for kidney nerve treatment

NCT ID NCT07462572

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study will test whether a personalized computer model, called a 'digital twin,' can predict which patients with high blood pressure will respond to a procedure called renal denervation. The study will enroll 60 people, including those with resistant hypertension, untreated hypertension starting medication, and those with a hormone condition called primary aldosteronism. Researchers will build each patient's digital twin from routine test results and see if it can accurately forecast blood pressure changes three months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital twin computer model
What this could lead to
If successful, this could help doctors personalize treatment decisions for high blood pressure, reducing unnecessary procedures and improving outcomes.
What could go wrong
This is a small pilot study (60 participants) that is not yet recruiting. The digital twin is a new tool and may not accurately predict responses in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients included in this study are recruited from the active patient population regularly seen in outpatient consultations or during hospitalization at the Hypertension Unit or the Pharmacology Unit of the Georges Pompidou European Hospital (Paris - France)

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General inclusion criteria: * Age between 18 and 90 years for both sexes. * Patient information and verbal non-opposition expressed by the patient, recorded in writing on the non-opposition form by the investigator. * Patients affiliated with social security or an equivalent scheme. Specific inclusion criteria: Patients with clinical indication for RDN: * Stable treatment for at least 1 month. * Clinical indication for RDN according to current recommendations or clinical judgment, as part of routine care. Patients with untreated primary hypertension: * Treatment-naïve hypertensive patients or continuous antihypertensive treatment for \< 6 months. * Office BP \>140/90 mmHg in repeated measures or office BP \>140/90 mmHg in a single visit and home BP or daytime 24h-ABPM BP \>135/85 mmHg. * Clinical indication to start antihypertensive treatment. Patients with clinical indication to surgical adrenalectomy: * Confirmed diagnosis of primary aldosteronism according to current guidelines. * Clinical indication for monoliteral surgical adrenalectomy. Exclusion Criteria: * Pregnancy. * Presence of skin irritation or non-intact skin at sensor attachment sites (sternum, chest, finger) preventing the possibility to pose sensors. * Known allergies to ultrasound gel, adhesives, Ag/AgCl electrodes, metals, or plastics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension hyperaldosteronism hypertensive disorder primary aldosteronism resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hypertension Unit - Georges Pompidou European Hospital

    Paris, France

  • Pharmacology Unit - Georges Pompidou European Hospital

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.